Exchange: NASDAQ·Updated 07:40 PM EST

SLXN News

News
all
press releases
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience (NASDAQ:LEXX) stockread more...
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience (NASDAQ:LEXX) stockread more...
Benzinga
More News
(RTTNews) - Wednesday, Silexion Therapeutics (SLXN) said the first patient has been dosed in its global Phase 2/3 trial evaluating SIL204 in patients with locally advanced pancreatic cancer (LAPC...
Nasdaq News: Markets
Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.
24-7 Market News
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%read more...
Benzinga
Silexion Therapeutics shares jump after hours on positive SIL204 preclinical findings for KRAS-driven cancers.read more...
Benzinga
Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN
24-7 Market News
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
Stocktwits
“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.
Stocktwits
Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.
Stocktwits
Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.
Stocktwits

Advertisement|Remove ads.